Aardvark Therapeutics (AARD) — Supplier relationships that shape the commercialization path

Aardvark Therapeutics operates as a clinical-stage biopharma that outsources virtually all manufacturing, distribution and investor communications while monetizing through equity issuance and eventual product commercialization. The company funds development and commercialization via public markets (including ATM/shelf programs) and strategic financings, while relying on contract manufacturers, distributors and professional services to execute trials and, later, supply chain operations. For investors and operators, the critical question is whether that outsourced model delivers scale reliably — and at what dilution or cost. For a concise supplier-risk summary, visit https://nullexposure.com/.

The high-level commercial thesis: capital-intensive R&D; outsourced execution; equity monetization

Aardvark generates value by advancing ARD-101 (and other candidates) through clinical milestones toward regulatory approval. It monetizes primarily through equity issuance — notably a $150 million at‑the‑market equity facility — and through milestone obligations embedded in third-party agreements. The business model is capital‑heavy, reliant on third-party manufacturing and distribution, and sensitive to financing terms and supply continuity.

What the supplier map looks like and why it matters

Across filings and press releases in early 2026, Aardvark’s external relationships fall into four practical buckets: capital markets & sales agents, transfer-agent/clearing infrastructure, professional services (legal, accounting, IR/media), and clinical/manufacturing/distribution partners (including scientific journals and niche treasury counterparties that reference Aardvark assets). That structure implies a lean headcount and high dependency on external vendors for execution and investor access.

• Capital access is active and material — Aardvark has an active equity distribution agreement that directly dilutes existing holders as needed.
• Supply and logistics are outsourced and critical — The company does not own manufacturing and depends on CMOs/CROs for trial and future commercial supply.
• Service relationships are standard for a late‑stage biotech — law firms, auditors, IR and media agencies and depositary/transfer agents are in place.

For a practical reading of counterparties and risk signals, see our platform at https://nullexposure.com/.

How Aardvark contracts and what that means for operators

Company‑level signals from filings indicate a contracting posture that is short‑term and spot-oriented, with purchase‑order based supply and no long-term manufacturing agreements disclosed. The supplier model shows: global trial footprint (U.S., U.K., South Korea, Romania, Italy, France, Spain, Canada, Australia), heavy reliance on third parties for manufacturing and distribution (critical), an active stage of engagements, and potential future contingent payments aggregated at roughly $180.5 million as of year‑end 2024 — a company-level indicator of meaningful future spend. These constraints collectively indicate operational leverage to service providers but concentration risk if key third parties fail to perform.

Detailed relationship run‑through (plain English, concise sources)

Nasdaq Global Select Market (NDAQ)

Aardvark’s common stock trades on the Nasdaq Global Select Market under the ticker AARD, providing primary market liquidity and public reporting obligations. According to the company’s S‑3 shelf registration filed in FY2026, the listing is explicitly noted. (StockTitan S‑3, FY2026)

Piper Sandler & Co. / Piper Sandler

Piper Sandler serves as Aardvark’s sales agent under an Equity Distribution Agreement establishing an ATM program of up to $150 million of common stock, enabling reactive capital raises. This arrangement is documented in the company’s March 23, 2026 filings and related press coverage. (8‑K and prospectus supplement; TradingView and StockTitan, FY2026)

The Depository Trust Company (DTC)

DTC is named as the likely depositary for book‑entry securities, facilitating institutional clearing and settlement for Aardvark’s issued debt and equity. The S‑3 prospectus references DTC as the depositary for securities issued in book‑entry form. (S‑3 shelf registration, FY2026)

Paul Hastings LLP

Paul Hastings LLP is Aardvark’s securities counsel, providing legal opinion on the validity of equity issuances under the prospectus. The S‑3 and prospectus supplement list Paul Hastings as counsel in Palo Alto. (Prospectus supplement, FY2026)

Equiniti Trust Company, LLC

Equiniti Trust Company is Aardvark’s transfer agent and registrar, managing shareholder records and dividend/distribution logistics. The S‑3 filing names Equiniti as the transfer agent and registrar. (S‑3 shelf registration, FY2026)

BDO USA, P.C.

BDO USA, P.C. is the independent registered public accounting firm that audited Aardvark’s consolidated financials for the years ended 2025 and 2024, a routine but material control for investor due diligence. The prospectus incorporates BDO’s audit report by reference. (Prospectus/424B5, FY2026)

Argot Partners

Argot Partners is listed as investor relations contact for Aardvark’s corporate press releases, handling investor inquiries and communications. This appears in multiple press releases announcing trial updates and financial results. (GlobeNewswire releases, FY2026)

Sam Brown LLC

Sam Brown LLC is Aardvark’s media relations firm handling press and media contacts for corporate announcements, as cited in recent PRs. (GlobeNewswire press releases, FY2026)

BofA Securities

BofA Securities is named among joint book‑running managers for Aardvark’s IPO process, indicating participation in earlier public offerings and underwriting syndicate activity. (StockTitan coverage of FY2026 IPO book‑running list)

Morgan Stanley

Morgan Stanley is also listed as a joint book‑running manager in the IPO syndicate, evidencing institutional underwriter relationships. (StockTitan IPO coverage, FY2026)

Cantor

Cantor (Cantor Fitzgerald group) appears as one of the joint book‑running managers for the IPO, completing the listed underwriting syndicate. (StockTitan IPO coverage, FY2026)

RBC Capital Markets

RBC Capital Markets is named among the joint book‑running managers for the IPO, rounding out the underwriting group that supported Aardvark’s public listing. (StockTitan IPO coverage, FY2026)

LITS (Lite Strategy, Inc.)

Lite Strategy, Inc. references Aardvark in relation to the sale of a clinical asset (ME‑344 / WE‑868) being developed for obesity at Aardvark, indicating Aardvark’s role as asset counterparty in a transaction referenced by LITS’ FY2025 disclosures. (LITS press and QuiverQuant/GlobeNewswire, FY2025–FY2026)

Molecular Metabolism

The peer‑reviewed journal Molecular Metabolism published clinical and preclinical data for Aardvark’s ARD‑101 program, providing third‑party scientific validation of trial data dissemination. (GlobeNewswire release referencing the journal, FY2026)

BofA Securities (duplicate handled above)

BofA appears multiple times in underwriting references; see the underwriter summary above. (StockTitan IPO coverage, FY2026)

Cantor (duplicate handled above)

Cantor’s role as a joint book‑runner is covered in the underwriting summary. (StockTitan IPO coverage, FY2026)

(Note: duplicate listings like “MS” and repeated Piper Sandler mentions are consolidated to avoid redundancy; each source entry above maps to the referenced filings and press releases in FY2025–FY2026.)

Risk implications for investors and operators — the bottom line

• Supply risk is operationally critical. Aardvark outsources all manufacturing and distribution and contracts are short‑term/spot oriented, increasing execution risk around scale‑up and time‑to‑market. This is a company-level signal drawn from prospectus language indicating purchase‑order relationships and lack of long‑term manufacturing agreements.
• Financing is explicit and dilutive. The $150 million ATM facility with Piper Sandler is a ready capital lever that supports runway but directly dilutes shareholders when used.
• Service ecosystem is mature but concentrated. Standard professional services (legal, audit, IR, transfer agent) are in place; however, reliance on third parties for manufacturing and trial execution confers concentration and quality‑control risk.
• Global trial footprint adds regulatory and logistical complexity. Operating across multiple jurisdictions increases vendor management burden and cost.

Actionable investor checklist

• Verify the existence and terms of any long‑term manufacturing or distribution agreements beyond purchase‑order arrangements.
• Monitor utilization of the Piper Sandler ATM (shares sold and pricing) to model dilution.
• Assess counterparty strength of current CMOs/CROs and any contingency plans for supply continuity.
• Track milestone payment contingencies (~$180.5 million reported in 2024) against cash runway and financing plans.

For an integrated view of Aardvark’s counterparty map and supplier risk scoring, explore our platform at https://nullexposure.com/.

Bold final takeaway: Aardvark is capital‑market driven and operationally outsourced — that structure accelerates trial execution but concentrates execution risk with third‑party manufacturers and distributors, and clearly links future commercialization to continued access to equity markets.